Xultophy 100/3.6 (insulin degludec and liraglutide; Novo Nordisk) injection is now available as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (<50 units daily) or liraglutide (≤1.8mg daily).
Xultophy 100/3.6 was initially approved by the FDA in November 2016. It contains 100 U/mL insulin degludec and 3.6mg/mL liraglutide, a combination of a long-acting human insulin analog and a glucagon-like peptide 1 (GLP-1) receptor agonist. Insulin degludec lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Liraglutide increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying.
Xultophy 100/3.6 carries a boxed warning regarding the risk of thyroid C-cell tumors. It is not indicated for use in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).
Xultophy 100/3.6 is available as 3mL prefilled single-use pens in 5-count packages.
For more information call (800) 727-6500 or visit Xultophy.com.